Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced recruitment of three additional pediatric patients in an investigator‑led Netherton syndrome study and reported positive 9‑month whole‑body data from the first pediatric subject.
The subject's Investigator's Global Assessment (IGA) improved from 4 (severe) at baseline to 0 (clear) at 9 months, and pruritus fell from 5 to 0. The subject reports zero nightly sleep disturbance, no need for prior medications (antibiotics, antivirals, antihistamines, glucocorticoids), and no adverse events after 9 months of continuous daily QRX003 whole‑body dosing. Two new pediatric subjects are in Austria and one is in Ireland; all will receive twice‑daily whole‑body QRX003 with a 12‑week initial period followed by a long‑term extension.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced the U.S. FDA has granted Orphan Drug Designation for QRX003 to treat Netherton Syndrome on Oct 21, 2025.
The FDA designation follows an EMA orphan designation in May 2025 and provides benefits including tax credits, fee waivers or reductions, and seven years of US market exclusivity if QRX003 is approved. QRX003 lotion (4%) is in two late‑stage pivotal whole‑body trials; enrollment is expected complete in Q1 2026, topline data is anticipated in H2 2026, and an NDA submission is planned later in 2026.
Quoin Pharmaceuticals (NASDAQ: QNRX) entered a private placement to raise up to $104.5 million in gross proceeds, including $16.5 million upfront and up to $88.0 million from cash exercise of accompanying warrants. The placement priced at $8.25 per ADS and includes 1,993,940 ADSs (or pre-funded warrants) and warrants to purchase up to 7,975,760 ADSs across four warrant series (H, I, J, K) with exercise prices from $9.075 to $12.375.
Participating healthcare investors include AIGH Capital, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine, ADAR1 Capital, and Velan Capital; Maxim Group is sole placement agent. Closing is expected on or about October 14, 2025. Proceeds are earmarked for R&D including completion of QRX003 pivotal development, operating expenses, and general corporate purposes; net proceeds are expected to fund the company into 2027.
Quoin Pharmaceuticals (NASDAQ: QNRX) has released the fifth episode of its NETHERTON NOW video series, featuring twin sisters Allie and Kaleigh Fasanella, both living with Netherton Syndrome. The episode highlights the physical, emotional, and social challenges of living with this rare genetic skin disease.
The sisters, who are successful freelance writers for major publications like Allure and Teen Vogue, share their experiences with unpredictable flare-ups, constant pain, and mental health challenges since being diagnosed in their first year of life. The video release coincides with Quoin's advancement of QRX003, their lead product candidate for Netherton Syndrome, currently in pivotal clinical trials with encouraging early data.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced that its NETHERTON NOW awareness campaign has achieved significant milestones, surpassing 1 million video views and 14 million impressions. The campaign, focused on raising awareness about Netherton Syndrome (NS), a rare genetic skin disease, has gained widespread exposure through major media outlets including MSN, Today, and CBS News.
The company's lead candidate, QRX003, is currently in late-stage clinical trials for treating Netherton Syndrome. The studies are evaluating the treatment both as monotherapy and in combination with off-label systemic treatments. Full enrollment for these trials is expected in early to mid-Q1 2026.
Quoin Pharmaceuticals (NASDAQ: QNRX) has appointed Sally Lawlor as its new Chief Financial Officer, effective immediately. Lawlor brings over 20 years of financial leadership experience, including her recent role at Sebela Pharmaceuticals and positions at Aptiv Plc and KPMG.
The appointment comes as Quoin advances its lead product QRX003 through pivotal clinical trials for Netherton Syndrome, with full enrollment expected in early to mid-Q1 2026. The company is preparing for a potential NDA filing next year and transition to a commercial-stage organization. Additionally, Quoin is developing treatments for Peeling Skin Syndrome and other rare dermatologic diseases through a novel topical rapamycin platform.
Quoin Pharmaceuticals (NASDAQ: QNRX) has released the fourth episode of its NETHERTON NOW video series, featuring Mandy Aldwin-Easton, a prominent patient advocate and leader in rare disease advocacy organizations. The episode highlights the devastating impact of Netherton Syndrome, a rare skin condition characterized by severe pain, chronic flare-ups, and frequent hospitalizations.
Mandy, who serves as Medical and Communications Manager of the UK-based Ichthyosis Support Group and President of the European Network for Ichthyosis, shares her personal journey with the condition. The release coincides with Quoin's advancement of QRX003, their lead product candidate for Netherton Syndrome treatment, which has shown promising results in ongoing pivotal clinical trials.
Quoin Pharmaceuticals (NASDAQ: QNRX) reported significant progress in Q2 2025 for its lead drug candidate QRX003. The company announced positive 6-month clinical data from its pediatric Netherton Syndrome study, showing significant skin improvements and reduced itching with no adverse events. The FDA cleared a second pivotal study for Netherton Syndrome, while initial positive data emerged from a Peeling Skin Syndrome study.
Notable regulatory achievements include receiving Orphan Drug Designation from the European Medicines Agency and Rare Pediatric Disease Designation from the FDA. Financially, Quoin reported $7.8 million in cash as of June 30, 2025, with runway into Q1 2026, and a Q2 net loss of $3.7 million primarily due to increased R&D spending.
[ "Positive 6-month clinical data from pediatric Netherton Syndrome study showing significant improvements", "FDA clearance for second pivotal study of QRX003", "Positive initial data from Peeling Skin Syndrome study", "Secured European Orphan Drug Designation providing 10 years market exclusivity", "Obtained FDA Rare Pediatric Disease Designation enabling Priority Review Voucher eligibility", "$7.8M cash runway extending into Q1 2026" ]Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled its Q2 2025 financial results release for August 7, 2025, before market opening.
The upcoming announcement will feature both financial results for the quarter ending June 30, 2025, and an operational update covering the company's key achievements and recent milestones.
Quoin Pharmaceuticals (NASDAQ: QNRX) provided an update on its rare disease product portfolio, highlighting progress in multiple clinical programs. The company's lead product, QRX003, is advancing in two pivotal registrational studies for Netherton Syndrome across multiple regions, with full recruitment targeted for early-mid Q1 2026.
The company reported positive initial data from its Peeling Skin Syndrome (PSS) study, showing significant improvements across key endpoints. Quoin's topical rapamycin program for various rare skin conditions continues to progress, with clinical testing expected to begin in H1 2026.
To optimize resources, Quoin has discontinued development of QRX007 for Netherton Syndrome and QRX004 for Epidermolysis Bullosa, focusing instead on more promising opportunities.